BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ASCEND Therapeutics, Inc. Raises Awareness Of Breast Pain And Density Concerns During National Women's Health Week


10/19/2005 5:11:15 PM

HERNDON, Va., May 10 /PRNewswire/ -- Dedicated to easing severe breast pain and other problematic breast-related conditions, ASCEND Therapeutics, a leading researcher and developer of pharmaceutical transdermal therapies, will make available interviews with key executives and medical researchers for journalists working on stories related to breast health during National Women's Health Week, May 9-15 2004.

"Few of us realize that breast pain afflicts nearly 75% of all premenopausal women, with up to 30% experiencing moderate to severe pain for more than 5 days a month. Yet, treatment for breast pain and other breast health conditions goes largely unrecognized," states Jay Bua, president and CEO of ASCEND Therapeutics. "We are focused on developing a transdermal therapy that can help reduce pain, discomfort and anxiety of cyclic mastalgia and other breast-related conditions."

ASCEND has been working aggressively since 2001 on treatments to alleviate benign breast disease. In Phase 2 trials at the present time, ASCEND Therapeutics' TamoGel(TM), a new estrogen inhibitor for transdermal application, is currently completing an international multi-center Phase 2 clinical trial to evaluate its efficacy in reducing or eliminating cyclic mastalgia, or breast pain, associated with menstrual cycle changes. Results from a second multi-center Phase 2 clinical trial to evaluate TamoGel(TM)'s efficacy in reducing breast density that can obscure mammogram readings are expected this summer.

Research conducted in the area of benign breast disease by D. N. Ader, Ph.D., of the National Institutes of Health, reveals that untreated cyclic mastalgia is a common problem that can be sufficiently severe in up to 30% of women under 55 to interfere with usual activities, and has been associated with elevated mammography usage in young women.

National Women's Health Week is a national effort by an alliance of government organizations to raise awareness about manageable steps women can take to improve their health. The focus is on the importance of incorporating simple preventive and positive health behaviors into everyday life. For more information on this important initiative, visit http://www.4woman.gov/whw/2004/Join-the-fun/factsheet.html

About ASCEND Therapeutics

ASCEND Therapeutics is a biopharmaceutical company focused on the use of transdermal drug delivery technology to overcome therapeutic barriers and raise the standard of care for certain chronic conditions. For more information about ASCEND, you may visit the company's Web site at http://www.ascendtherapeutics.com/

ASCEND Therapeutics

CONTACT: Elizabeth Maybach of The SheaHedges Group, +1-703-287-7821, oremaybach@sheahedges.com, for ASCEND Therapeutics



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES